WO2016208556A1 - Composition relaxante - Google Patents

Composition relaxante Download PDF

Info

Publication number
WO2016208556A1
WO2016208556A1 PCT/JP2016/068331 JP2016068331W WO2016208556A1 WO 2016208556 A1 WO2016208556 A1 WO 2016208556A1 JP 2016068331 W JP2016068331 W JP 2016068331W WO 2016208556 A1 WO2016208556 A1 WO 2016208556A1
Authority
WO
WIPO (PCT)
Prior art keywords
noble metal
composition
relaxing
fine particles
application
Prior art date
Application number
PCT/JP2016/068331
Other languages
English (en)
Japanese (ja)
Inventor
廣至 岩城
Original Assignee
プラチナブブ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラチナブブ株式会社 filed Critical プラチナブブ株式会社
Priority to JP2017524906A priority Critical patent/JPWO2016208556A1/ja
Publication of WO2016208556A1 publication Critical patent/WO2016208556A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a novel use of noble metal fine particles.
  • the electroencephalogram is a comprehensive view of various electrical activities in the cranial nerve cells from the top of the scalp.
  • a ⁇ wave of less than 4 Hz a ⁇ wave of 4 Hz to less than 8 Hz, an ⁇ wave of 8 Hz to less than 13 Hz, and 13 Hz.
  • the ⁇ wave is a wave around 10 Hz that appears greatly in the occipital region when the eyes are closed, and is an index of a brain activity suppression system.
  • Alpha waves increase as you relax, but decrease when you open your eyes, use your brain for mental arithmetic, or think. For this reason, ⁇ waves are regarded as an effective indicator of a relaxed state.
  • Patent Documents 1 and 2 It is known that when noble metal fine particles are dispersed in water as a colloid, they have a reducing power, that is, an electron donating property (Patent Documents 1 and 2). It has been reported that an aqueous solution containing platinum colloid has a function of eliminating active oxygen in the body and has various effects beneficial to living bodies (Patent Documents 2 to 5). Moreover, cosmetics containing platinum colloid have been reported to improve various skin symptoms (Patent Documents 6 and 7). However, it is not known that such cosmetics have a relaxing effect.
  • the present invention aims to provide a novel use of noble metal fine particles.
  • the present inventor has found that noble metal fine particles have a relaxing effect by electroencephalogram measurement, and completed the present invention.
  • the present invention provides the following. 1. A relaxing composition comprising precious metal particulates. 2. 2. The relaxing composition as described in 1 above, wherein the noble metal fine particles are platinum fine particles. 3. 3. The relaxing composition as described in 1 or 2 above, wherein the noble metal fine particles have an average single particle size of about 2 to about 5 nm. 4). 4. The relaxing composition according to any one of 1 to 3, further comprising a base, wherein the noble metal fine particles are dispersed in the base as colloidal particles. 5. 5. The relaxing composition as described in any one of 1 to 4 above, wherein the noble metal fine particles are produced by a metal salt reduction reaction method. 6). 6. The relaxing composition as described in any one of 1 to 5 above, which is externally applied to the skin. 7).
  • a method for relaxing a subject comprising applying to the subject a composition as defined in any one of 1 to 6 above. 8). Use of a composition as defined in any one of 1 to 6 above for relaxing a subject. 9. Use of the composition as defined in any one of 1 to 6 above as a relaxing composition. 10. Use of the composition defined in any one of 1 to 6 above for the manufacture of a relaxing composition.
  • a relaxing composition containing noble metal fine particles and a method of relaxing an object with the composition.
  • the electrode position used for the electroencephalogram measurement is shown.
  • the relative change of alpha wave average power by an experimental sample is shown.
  • the right graph shows the results of each subject, and the left graph shows the mean ⁇ standard error of the results of two subjects.
  • the relative change of alpha wave average power by a control sample is shown.
  • the right graph shows the results of each subject, and the left graph shows the mean ⁇ standard error of the results of two subjects.
  • coating of a use experienced person group is shown.
  • the right graph shows the results of each subject, and the left graph shows the mean ⁇ standard error of the results of 8 subjects.
  • coating of an unused user group is shown.
  • the right graph shows the results of each subject, and the left graph shows the mean ⁇ standard error of the results of 8 subjects.
  • the relative change in the average ⁇ wave power of the group of experienced users is shown.
  • the relative change of the ⁇ wave average power of the unused user group is shown.
  • the relative change in ⁇ wave average power of each user (8 persons) is shown.
  • the relative change of alpha wave average power of each unused user (8 persons) is shown.
  • coating of all the test subjects is shown.
  • the right graph shows the results of each subject, and the left graph shows the mean ⁇ standard error of the results of 16 subjects.
  • the relative change of alpha wave average power of all subjects is shown.
  • the relative change of alpha wave average power of each subject (16 persons) is shown.
  • the noble metal fine particles in the present invention have an average single particle size of nanometer order, preferably about 2 to about 20 nm, more preferably about 2 to about 10 nm, and still more preferably about 2 to about 5 nm.
  • the particle diameter of the noble metal fine particles can be measured by electron microscope observation (TEM observation), for example, using an HF-2000 type field emission transmission electron microscope (Hitachi Co., Ltd.) (Japanese Patent Laid-Open No. 2002-212102).
  • the noble metal platinum, palladium, gold or silver is exemplified.
  • the noble metal fine particles in the present invention are preferably platinum fine particles.
  • the method for producing the noble metal fine particles is not particularly limited, but a metal salt reduction reaction method is exemplified.
  • a metal salt reduction reaction method is exemplified.
  • the method uses a water, noble metal ion solution, a reducing agent, a pH compensator, and a surfactant to produce a noble metal colloid-containing aqueous solution.
  • the noble metal ion solution is an aqueous solution of a noble metal halide, for example, an aqueous solution of chloroplatinic acid, chloropalladic acid, chloroauric acid, or silver nitrate.
  • the noble metal ion solution is prepared by dissolving a commercially available noble metal halide in water.
  • a chloroplatinic acid aqueous solution is preferably used.
  • Surfactant is added as a dispersion stabilizer to prevent precipitation and aggregation of the noble metal colloid.
  • Any known surfactant may be used as the surfactant, and examples thereof include nonionic surfactants such as polysorbate 80 and glycerin fatty acid ester.
  • the glycerin fatty acid ester those having an HLB of 10 or more are suitable. For example, those having a polymerization degree of around 10 and fatty acids of lauric acid, stearic acid or oleic acid, and an esterification degree of 8 to 9% can be used. .
  • glycerin fatty acid esters for example, L-10D (Mitsubishi Chemical Foods Co., Ltd.), J-0381V (RIKEN Vitamin Co., Ltd.), and MSW-7S (Sakamoto Yakuhin Kogyo Co., Ltd.) are commercially available. Moreover, it replaces with surfactant and saccharides like starch can be used as a dispersion stabilizer.
  • polysorbate 80 is preferably used.
  • the reducing agent is for reducing noble metal ions, and for example, a low molecular alcohol such as ethanol is preferably used.
  • the pH compensator adjusts the pH of a reaction solution that becomes acidic by addition of a noble metal ion solution to neutral or weak alkalinity. Therefore, it is preferable to add the pH compensator simultaneously with the noble metal ion solution.
  • the pH compensator is preferably an alkali metal such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, or sodium bicarbonate, and particularly preferably sodium bicarbonate.
  • the operation for preparing the noble metal colloid is, for example, as follows. First, water is heated while stirring, and after reaching a certain temperature, a surfactant or a dispersion stabilizer and a reducing agent are added. Next, a noble metal ion solution and a pH compensator are simultaneously added to this solution. The reducing agent acts on the noble metal ion, and the reduction reaction of the noble metal ion proceeds in water. Stirring is continued while keeping the temperature of the liquid constant, and heating and stirring are terminated when the noble metal ions are reduced. Reduction of the noble metal ion can be confirmed by changing the liquid color to black in the case of platinum, palladium, etc., changing to red purple in the case of gold, and changing to yellowish black in the case of silver. The reduction treatment temperature is in the range of 50 to 75 ° C., preferably around 70 ° C. As a result of the reduction treatment, a noble metal colloid is obtained in the reaction solution.
  • the precious metal concentration of the precious metal ion solution is not limited.
  • chloroplatinic acid aqueous solution (20% w / v) those containing noble metal ions in an amount of 1/5 by mass (g) / volume (ml) ratio are exemplified.
  • the amount (ml) of water is 400 to 2000 times that of the noble metal ion solution 1.
  • the amount of the reducing agent and the pH compensator may be appropriately determined depending on the type of noble metal.
  • the amount of reducing agent (ml) is 99.5% alcohol, 20 to 100 times the precious metal ion solution, and the amount (ml) of the pH compensator is The concentration is 5% (wt%), which is 10 to 30 times that of the noble metal ion solution.
  • the amount (g) of the surfactant is 1 to 10 times the amount (g) of the noble metal in the noble metal ion solution.
  • the amount used (g) is 1 to 3 times, preferably 2 times the amount of noble metal (g) in the noble metal ion solution (Japanese Patent Laid-Open No. 2005-163117).
  • the amount of starch is almost the same as that of glycerin fatty acid ester.
  • Controlling the amount of the surfactant or dispersion stabilizer to 1 to 10 times the amount of the noble metal in the noble metal ion solution ensures the stability of the produced noble metal colloid.
  • the amount of water is larger than the amount of the noble metal ion solution, the concentrations of the noble metal ions, the reducing agent, and the pH compensator in the reaction solution are relatively lowered, which causes a problem in the dispersion stability of the produced noble metal colloid.
  • the noble metal concentration exceeds 2000 ppm in the reduction treatment step, the dispersion stability deteriorates.
  • a reducing agent and a surfactant are added to water to form a reducing atmosphere in the liquid, and then the noble metal ion solution is added.
  • An agent may be added, and after reaching a certain temperature, a noble metal ion solution and a pH compensator may be added, and then a reducing agent may be added to form a reducing atmosphere in the solution.
  • a cleaning and purification treatment by filtration is performed in order to prevent contamination of dust and the like, to remove low molecular ions other than the noble metal colloid, and to desalinate.
  • the desalting treatment can be achieved by a conventional method, for example, by dialysis using an ultrafiltration membrane. After confirming that no electrolyte is detected in the permeate, the cleaning and purification treatment is completed. By selecting the filter paper used and the pore size of the ultrafiltration membrane, the particle size of the noble metal colloid can be guaranteed.
  • the concentration of the noble metal in the aqueous solution containing the noble metal colloid can be arbitrarily adjusted in this step, but it is preferable to adjust the concentration within the range of 200 to 5000 ppm by using an ultrafiltration device in consideration of economy.
  • concentration of 95 to 105% by weight is allowed with respect to the specified concentration and 200 ppm, 500 ppm or 2000 ppm is specified, aqueous solutions containing noble metal colloids of 190 to 210 ppm, 475 to 525 ppm or 1900 to 2100 ppm are obtained, respectively.
  • the water molecules around the noble metal colloid form an electric double layer with the minus (OH +) side facing the noble metal fine particle side and the minus (OH-) side facing outward due to the minus charge of the noble metal fine particles.
  • the charge of the noble metal colloid is expressed by a zeta potential considering this electric double layer.
  • the noble metal colloid produced by the above method preferably has a zeta potential of minus ( ⁇ ) 20 mV to minus ( ⁇ ) 60 mV.
  • the zeta potential can be measured by an electrophoretic light scattering method (Japanese Patent Laid-Open No. 2002-212102).
  • the noble metal colloid containing aqueous solution used for manufacture of the composition of this invention does not contain electrolyte substantially.
  • substantially free of electrolyte means that the electrolyte concentration is less than 0.001 wt% in terms of NaCl.
  • the noble metal fine particle is a method of producing a platinum colloid by reducing platinum ions using a platinum ion solution, water, a nonionic surfactant, a pH compensator and a reducing agent.
  • a chloroplatinic acid aqueous solution is used as a platinum ion solution
  • polysorbate 80 is used as a nonionic surfactant
  • sodium hydrogen carbonate is used as a pH compensator
  • ethanol is used as a reducing agent.
  • composition of the present invention can contain bases and / or additives common to the dosage form and product form in addition to the precious metal fine particles.
  • the noble metal colloid-containing aqueous solution obtained as described above can be further concentrated or dehydrated if necessary, and mixed with other components to obtain the composition of the present invention.
  • the amount of the noble metal fine particles in the composition of the present invention is not limited, but is, for example, about 0.0001 to about 1% by weight, preferably about 0.001 to about 0.1% by weight, and more preferably about 0.001. 001 to about 0.03% by weight, even more preferably about 0.01 to about 0.03% by weight.
  • the noble metal fine particles are preferably dispersed in the base as colloidal particles.
  • the base is preferably an aqueous base, and examples thereof include water, glycerin, diglycerin, polyethylene glycol, carbomer, butylene glycol, sorbitol, and a mixture of two or more thereof.
  • the composition of the present invention preferably contains water as a base.
  • the noble metal colloid-containing aqueous solution obtained as described above may be mixed with a base and / or additive other than water.
  • the composition of the present invention comprises 50 wt% or more, preferably 60 wt% or more, more preferably 70 wt% or more water. As long as it is emulsified with water, it may contain an oil component.
  • the composition of the present invention is externally applied to the skin, scalp, or hair, and can be provided as cosmetics, quasi drugs, or pharmaceuticals.
  • the subject to which the composition of the present invention is applied is a mammal, typically a human.
  • the dosage form and product form of the composition of the present invention are not particularly limited, and may be a general dosage form and product form.
  • Examples of the dosage form of the composition of the present invention include an oil-in-water type, a water-in-oil type, a water-dispersed type, a pressed shape, a solid, and a powder.
  • Examples of the product form include lotion, milky lotion, cream, beauty essence, pack, shampoo, hair styling agent, perfume, face wash and the like.
  • the product form may be a sheet form impregnated with the composition of the present invention.
  • the composition of the present invention is preferably applied externally to the skin or scalp, more preferably to the skin.
  • composition of the present invention can increase ⁇ waves and has a relaxing effect.
  • the ⁇ wave can be measured according to the method described in the examples or by other general methods for measuring an electroencephalogram.
  • the present invention also provides a method for relaxing a subject comprising applying the composition of the present invention to the subject, particularly the subject's skin, scalp, or hair.
  • Figure 1 shows the electrode positions used for this measurement.
  • the potential difference between the binaural ears (A1, A2) and each scalp electrode was taken, and the time-series change was taken into the computer at a sampling frequency of 200 Hz.
  • the analysis is performed at a high speed of 1024 points as a unit by selecting a place where there is no artifact (electric potential fluctuation due to eye or body movement, electromyogram, external noise, etc.) for each situation, and where the brain waves appear cleanly.
  • Fourier transform (FFT) was performed by window function hamming, a power spectrum was obtained from the average of 6 units (about 30 seconds), and a power value for each frequency band was calculated. A map of each band was created by potential display based on the value.
  • the frequency bands used are as follows. ⁇ wave: 2.0 to 3.8 Hz ⁇ wave: 4.0 to 7.8 Hz ⁇ wave: 8.0 to 12.8 Hz ⁇ wave: 13.0 to 29.8 Hz
  • the peak frequency was calculated from O1 and O2.
  • the left and right sides are almost the same, but when they are slightly different, the average of O1 and O2 or Pz is also obtained by reference.
  • the forehead often has a lower frequency than the back of the head, but the peak frequencies of all channels are not so different.
  • the amount of the experimental sample and the control sample was 0.44 ⁇ 0.01 g, corresponding to 0.088 ⁇ 0.002 mg of platinum in the experimental sample. After application, the blindfold was removed. In the second trial, the sample to be applied was exchanged between subjects. (4) Stress task In order to make it easier to detect the relaxation effect, the Uchida-Kraepelin test (registered trademark) was performed for 10 minutes as a stress task before the sample application. Table 1 shows the progress of a series of experiments including other issues.
  • EEG changes in the alpha band when using the experimental sample and the control sample were examined. Since the magnitude of the ⁇ wave varies from person to person, the following analysis is based on the ⁇ wave band average power of the Fp1, Fp2, O1, O2, Fz, and Pz poles of the first resting eye (rest 1) of each trial. Relative changes were analyzed in decibel dB. The subject of analysis was resting eye data.
  • the ⁇ wave average power of the two subjects showed the same change pattern.
  • the ⁇ -wave average power decreased immediately after application, and the average power increased 17 minutes after application.
  • a relaxing effect characteristic of the experimental sample was observed in the change of the ⁇ -wave average power.
  • Example 2 In the same manner as in Example 1, the experiment was conducted with 16 females (average age 41.9 ⁇ 6.3 years old) from 33 to 52 years old who had makeup habits as subjects. Eight people (S1 to S8) had experience using the test sample serum for several weeks to about 2 years (group of experienced users), and the remaining 8 (S9 to S16) had no experience (unused) group). The results are shown in FIGS. 4 to 9 and Tables 3 to 6.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition relaxante comprenant des microparticules de métal précieux et un procédé permettant de relaxer un patient à l'aide de ladite composition.
PCT/JP2016/068331 2015-06-22 2016-06-21 Composition relaxante WO2016208556A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017524906A JPWO2016208556A1 (ja) 2015-06-22 2016-06-21 リラックス用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015-124637 2015-06-22
JP2015124637 2015-06-22

Publications (1)

Publication Number Publication Date
WO2016208556A1 true WO2016208556A1 (fr) 2016-12-29

Family

ID=57585832

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2016/068331 WO2016208556A1 (fr) 2015-06-22 2016-06-21 Composition relaxante

Country Status (2)

Country Link
JP (1) JPWO2016208556A1 (fr)
WO (1) WO2016208556A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1179981A (ja) * 1997-09-09 1999-03-23 Tokuriki Honten Co Ltd 消炎・沈痛貼付剤
JP2001122723A (ja) * 1999-10-27 2001-05-08 I Betsukusu:Kk 化粧品
JP2002212102A (ja) * 2001-01-23 2002-07-31 Ainobekkusu Kk 電気化学的生理活性微粒子
WO2003035084A1 (fr) * 2001-10-25 2003-05-01 Phild Co., Ltd. Dispersion aqueuse extra fine de metal precieux pour le massage de la tete
WO2004073723A1 (fr) * 2003-02-20 2004-09-02 She Tec Co., Ltd. Medicament therapeutique contenant de fines particules de metal noble
WO2006038528A1 (fr) * 2004-10-05 2006-04-13 Inovex Co., Ltd. Préparation et méthode prophylactiques ou thérapeutiques contre un symptôme mental
WO2011152005A1 (fr) * 2010-05-31 2011-12-08 株式会社資生堂 Agent sympatholytique, et produit cosmétique, produit alimentaire et articles divers contenant celui-ci
WO2015125963A1 (fr) * 2014-02-21 2015-08-27 幸子 島津 Minerai naturel contenant de l'huile thérapeutique

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1179981A (ja) * 1997-09-09 1999-03-23 Tokuriki Honten Co Ltd 消炎・沈痛貼付剤
JP2001122723A (ja) * 1999-10-27 2001-05-08 I Betsukusu:Kk 化粧品
JP2002212102A (ja) * 2001-01-23 2002-07-31 Ainobekkusu Kk 電気化学的生理活性微粒子
WO2003035084A1 (fr) * 2001-10-25 2003-05-01 Phild Co., Ltd. Dispersion aqueuse extra fine de metal precieux pour le massage de la tete
WO2004073723A1 (fr) * 2003-02-20 2004-09-02 She Tec Co., Ltd. Medicament therapeutique contenant de fines particules de metal noble
WO2006038528A1 (fr) * 2004-10-05 2006-04-13 Inovex Co., Ltd. Préparation et méthode prophylactiques ou thérapeutiques contre un symptôme mental
WO2011152005A1 (fr) * 2010-05-31 2011-12-08 株式会社資生堂 Agent sympatholytique, et produit cosmétique, produit alimentaire et articles divers contenant celui-ci
WO2015125963A1 (fr) * 2014-02-21 2015-08-27 幸子 島津 Minerai naturel contenant de l'huile thérapeutique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAWAGUCHIYA, S. ET AL.: "Assesment of the benefits of skin care and facial massage by measuring cerebral blood flow changes", FRAGRANCE JOURNAL, vol. 42, no. 8, 15 August 2014 (2014-08-15), pages 25 - 32 *
KOKUBO, H. ET AL.: "EEG Measurements on Relaxation Caused by Applying Essence of Colloidal Platinum", JOURNAL OF INTERNATIONAL SOCIETY OF LIFE INFORMATION SCIENCE, vol. 34, no. 1, March 2016 (2016-03-01), pages 61, XP055340637, ISSN: 1341-9226 *

Also Published As

Publication number Publication date
JPWO2016208556A1 (ja) 2018-06-07

Similar Documents

Publication Publication Date Title
CN110327261B (zh) 一种紧致肌肤用护肤组合物及其制备方法
JP4926312B2 (ja) 白金コロイド含有化粧品
DE69533813T2 (de) Formulierungen und Verfahren zur Verminderung von Hautirritationen
EP3162762B1 (fr) Particules de silice poreuses, leur procédé de production, et produit cosmétique composé les contenant
EP0645997B1 (fr) Cosmetique contenant des phospholipides et des composes fluorocarbones
KR20140012981A (ko) 수소를 발생하는 조성물
CN113117051B (zh) 一种抗衰老透皮多肽制剂及其制备方法
EP3632849B1 (fr) Particules creuses et cosmétiques les contenant
WO2022068173A1 (fr) Inclusion de rétinol, son procédé de préparation et son utilisation
CN110613641A (zh) 一种零防腐组合物及其在化妆品中的应用
JP5863230B2 (ja) オキサゾリジン−２−オン化合物をカプセル化するリポソーム
NZ297736A (en) Cosmetic composition containing kaolin and spherical particles of silicon dioxide or titanium dioxide
WO2015065009A1 (fr) Procédé d'encapsulation physique, dans une particule d'hydrogel, d'un liposome contenant une substance active, et composition cosmétique contenant celle-ci
CN108324581B (zh) 脂质体、脂质体液和化妆品、以及制造上述脂质体的方法
CN110585085A (zh) 一种纳米金软膜粉组合物及其制备方法和应用
WO2016208556A1 (fr) Composition relaxante
JP2008063295A (ja) 白金／銀コロイドを含有する皮膚外用剤
ES2553055T3 (es) Composiciones dermocosméticas basadas en una asociación sinérgica de plata coloidal y ácido desoxirribonucleico
WO2012101473A1 (fr) Compositions nanocomposites et procédé de traitement de soin pour la peau destiné à rajeunir et à corriger des défauts de la peau
KR102062345B1 (ko) 미세먼지 차단에 효과적인 수산화알루미늄 입자
TW200916118A (en) External preparation for skin
Gataoullin et al. Production and stabilization of fullerene dispersions in liquid media in the presence of nonionic surfactants
KR20130103199A (ko) 졸음운전 방지용 조성물
JP2002356415A (ja) イオン的緩衝帯形成化粧品
CN105267122B (zh) 一种天然保湿收缩毛孔啫喱及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16814326

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017524906

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16814326

Country of ref document: EP

Kind code of ref document: A1